WELCOME

We would like to personally welcome each of you to the second annual conference of Ketotic Hypoglycemia International. We are hosting a virtual conference to make sure everyone has a chance to join, no matter where in the world they live. All of the presentations will be available after the conference for educational purposes. Please feel free to share this conference invitation with whoever could be interested in learning more about idiopathic ketotic hypoglycemia – colleagues, family members, friends, doctors, medical students, industry partners – everyone is welcome!

We are beyond excited to have this opportunity to come together, patients, caregivers, healthcare professionals, leading medical experts, pharma- and biotech companies to share current knowledge, ongoing studies, best practices, patient stories, and our collective vision for the future. Our goal with the conference is to unite the families affected by idiopathic ketotic hypoglycemia, the experts, the healthcare professionals, and the industry so we together can take the first step towards an enhanced understanding of idiopathic ketotic hypoglycemia. We have a line-up of presentations made by our scientific advisory board and guest speakers, mixed up with patient stories from our KHI families from around the world. Our speakers will be ready to answer questions after each scientific presentation and in the “Meet the Experts” sessions. We hope you leave the conference inspired and informed on the latest knowledge in the field of idiopathic ketotic hypoglycemia.

If you are a patient, a caregiver, a family member, a nurse, a dietitian, a medical student, a researcher, a pharma- or biotech company, or something completely different: Your interest is truly our greatest asset today and tomorrow. We could not accomplish what we do without your support. Do you have a burning question for the experts? Please e-mail danielle.drachmann@ketotichypoglycemia.com, or submit your question in the registration form. See you virtually on June 11-12 2022

With gratitude on behalf of the entire staff team,

Danielle Drachmann
Executive Director
Nick Rasmussen
Marketing Lead

TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Time Zones</th>
<th>04-05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td>06-07</td>
</tr>
<tr>
<td>Meet Our Experts</td>
<td>08-09</td>
</tr>
<tr>
<td>Welcoming Our Latest Experts</td>
<td>10-11</td>
</tr>
<tr>
<td>What Is Ketotic Hypoglycemia?</td>
<td>12-13</td>
</tr>
<tr>
<td>What Is This Organization About?</td>
<td>14</td>
</tr>
<tr>
<td>Where To Find Us</td>
<td>15</td>
</tr>
<tr>
<td>Poster</td>
<td>16-17</td>
</tr>
<tr>
<td>Sponsors</td>
<td>18</td>
</tr>
</tbody>
</table>
# TIME ZONES

The following timeframes, specify when the conference will be happening in each particular country and zone.

<table>
<thead>
<tr>
<th>Country/Zone</th>
<th>Time Frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>DENMARK (CEST)</td>
<td>04:00PM - 08:30PM</td>
</tr>
<tr>
<td>WEST COAST USA (PDT)</td>
<td>07:00AM - 11:30AM</td>
</tr>
<tr>
<td>MOUNTAIN ZONE USA (MDT)</td>
<td>08:00AM - 12:30PM</td>
</tr>
<tr>
<td>CENTRAL USA (CDT)</td>
<td>09:00AM - 01:30PM</td>
</tr>
<tr>
<td>EAST COAST USA (EDT)</td>
<td>10:00AM - 02:30PM</td>
</tr>
<tr>
<td>UNITED KINGDOM (BST)</td>
<td>03:00PM - 07:30PM</td>
</tr>
<tr>
<td>SOUTH/CENTRAL AFRICA (SAST/CAT)</td>
<td>04:00PM - 08:30PM</td>
</tr>
<tr>
<td>MOSCOW, RUSSIA (MSK)</td>
<td>05:00PM - 09:30PM</td>
</tr>
<tr>
<td>UNITED ARAB EMIRATES (GST)</td>
<td>06:00PM - 10:30PM</td>
</tr>
<tr>
<td>INDIA (IST)</td>
<td>07:30PM - 12:00PM</td>
</tr>
<tr>
<td>CHINA (CST)</td>
<td>10:00PM - 02:30AM(+1)</td>
</tr>
<tr>
<td>JAPAN (JST)</td>
<td>11:00PM - 03:30AM(+1)</td>
</tr>
<tr>
<td>SYDNEY, AUSTRALIA (AEST)</td>
<td>00:00AM(+1) - 04:30AM(+1)</td>
</tr>
<tr>
<td>NEW ZEALAND (NZDT)</td>
<td>02:00AM(+1) - 06:30AM(+1)</td>
</tr>
</tbody>
</table>

Time slots listed on the program are in CEST.
<table>
<thead>
<tr>
<th>Time CEST</th>
<th>Description</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>04:00pm-04:15pm</td>
<td><strong>Opening session</strong></td>
<td>Danielle Drachmann, Executive Director of Ketotic Hypoglycemia International</td>
</tr>
<tr>
<td>04:00pm-04:05pm</td>
<td>Welcome</td>
<td>Danielle Drachmann, Executive Director of Ketotic Hypoglycemia International</td>
</tr>
<tr>
<td>04:05pm-04:15pm</td>
<td><strong>Opening session</strong></td>
<td>Jake Petersen, Chairman</td>
</tr>
<tr>
<td>04:15pm-07:05pm</td>
<td><strong>Understanding ketotic hypoglycemia</strong></td>
<td>Dr. Anne Benner, Odense University Hospital, Denmark</td>
</tr>
<tr>
<td>04:15pm - 04:25pm</td>
<td>The roadmap to diagnosis: Establishing incidence, prevalence, subtypes, and a diagnostic protocol for ketotic hypoglycemia</td>
<td>Dr. Anne Benner, Odense University Hospital, Denmark</td>
</tr>
<tr>
<td>04:25pm-04:55pm</td>
<td>What is hypoglycemia? - 10 min. Patient story or/and Q&amp;A</td>
<td>Dr. Paul Thornton, Cook Children's Hospital, US</td>
</tr>
<tr>
<td>04:45pm-05:15pm</td>
<td>What is ketotic hypoglycemia? - 10 min. Patient story or/and Q&amp;A</td>
<td>Dr. David Weinstein, Passage Bio, US</td>
</tr>
<tr>
<td>05:15pm-06:00pm</td>
<td>Adaptation to fasting in children - 10 min. Patient story or/and Q&amp;A</td>
<td>Dr. Joseph Wolfsdorf, Boston Children's Hospital, US</td>
</tr>
<tr>
<td>06:00pm-06:30pm</td>
<td>The role of fasting studies in the diagnosis and management of ketotic hypoglycemia - 10 min. Patient story or/and Q&amp;A</td>
<td>Dr. Paul Thornton, Cook Children's Hospital, US</td>
</tr>
<tr>
<td>06:30pm-07:00pm</td>
<td>Idiopathic ketotic hypoglycemia in adults - a case presentation - 10 min. Patient story or/and Q&amp;A</td>
<td>Dr. Mary-Elizabeth Patti, The Hypoglycemia Clinic, Joslyn Diabetes Center, US</td>
</tr>
<tr>
<td>07:00pm</td>
<td>15 min. break</td>
<td></td>
</tr>
<tr>
<td>07:20pm-07:40pm</td>
<td><strong>Following up on projects from last year's conference</strong></td>
<td>Dr. Henrik Thybo Christesen, Odense University Hospital, Denmark</td>
</tr>
<tr>
<td>07:20pm-07:45pm</td>
<td>GS(D)Xa and KH - 10 min. Patient story or/and Q&amp;A</td>
<td>Dr. Henrik Thybo Christesen, Odense University Hospital, Denmark</td>
</tr>
<tr>
<td>07:45pm-07:55pm</td>
<td>Ketotic hypoglycemia in patients with Down syndrome</td>
<td>Austin Carrigg, Ketotic Hypoglycemia International</td>
</tr>
<tr>
<td>07:55pm-08:25pm</td>
<td>Learning from the field of Patient Advocacy</td>
<td>Bastian Hauck, #DietsDiabetes Online Community</td>
</tr>
<tr>
<td>08:25pm-08:40pm</td>
<td>Closing session</td>
<td>Danielle Drachmann, Executive Director of Ketotic Hypoglycemia International</td>
</tr>
<tr>
<td>08:30pm-08:50pm</td>
<td>Meet the experts: - Your questions answered by the Scientific Advisory Board</td>
<td>Danielle Drachmann, Executive Director of Ketotic Hypoglycemia International</td>
</tr>
<tr>
<td>08:50pm-09:25pm</td>
<td>Closing remarks</td>
<td>Danielle Drachmann, Executive Director of Ketotic Hypoglycemia International</td>
</tr>
</tbody>
</table>
MEET OUR EXPERTS

Ketotic Hypoglycemia International aims to challenge current perceptions and attitudes to expand the recognition that IKH can be more than a normal variation and establish an international platform for future research collaboration. Our mission is supported by leading medical experts within the field of inherited metabolic diseases, pediatric endocrinology, and endocrinology united in our Scientific Advisory Board.

Dr. Henrik Christesen
Odense University Hospital, Denmark

Henrik Thybo Christesen is a clinical professor at Hans Christian Andersen Children’s Hospital, Odense University Hospital, Denmark and a pediatric endocrinologist with special clinical and research interest in hypoglycemia. He leads the multidisciplinary national team in complex hypoglycemia at the hospital, also receiving international patients. Through international collaboration, his research has led to many published papers in the field, mostly on congenital hyperinsulinism, but also, more recently, on ketotic hypoglycemia. Of more than 110 papers, he has published over 40 papers on glucose disorders and beta cells. He functions as the head of the scientific advisory board in Ketotic Hypoglycemia International.

Dr. Paul Thornton
Cook Children’s Hospital, US

Paul Stephen Thornton is a Medical Director, Distinguished Consultant of the Endocrinology/Diabetes Clinic and the Hyperinsulinism Center at Cook Children’s Medical Center, in Fort Worth, Texas. His recent awards include the Cook Children’s Clinical Scholar Award 2012-2014 and recipient of the 2012 Cook Children’s Health Care System Endowed Chair Award. He has coauthored more than a dozen book chapters and over 50 journal articles. Paul is the lead author of the recent Pediatric Endocrine Society’s Recommendations and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. Dr. Thornton is also a member of the Pediatric Endocrine Society, society for Pediatric Research, and The Endocrinology Society.

“Through my work with children with idiopathic ketotic hypoglycemia, it struck me that many of them really have a disease being much more than normal variation. This has prompted us to dive into various genetic explanations and improved management and treatment.”

- Dr. Henrik Christesen

Dr. Terry Derks
Beatrix Children’s Hospital, The Netherlands

Terry Derks has been certified as consultant pediatric metabolic diseases and he is appointed as associate professor at the University Medical Center Groningen, University of Groningen, the Netherlands. Since his PhD thesis defense in 2007 (title, “MCAD deficiency: clinical and laboratory studies”), he developed a special interest, both clinically and scientifically, in inherited disorders of glyceroneogenesis (i.e. hepatic glycogen storage diseases) and fatty acid oxidation disorders. Dr. Derks has more than 60 international publications, 2 book chapters and is a SSIEM Advisory Council Member. In MetabERN Dr. Derks is a Medical Executive Board member and the Work package leader for the “Virtual Counseling Framework”.

Dr. Pratik Shah
The Royal London Children’s Hospital, UK

Pratik Shah is a Consultant in Pediatric Endocrinology/Diabetes and Honorary Senior Lecturer at The Royal London Children’s Hospital (Barts Health NHS Trust) and Queen Mary University of London (QMUL), London. He did his PhD in the field of Congenital Hyperinsulinism and specializes in children with all forms of glucose disorders and has led the highly specialized service for Congenital Hyperinsulinism. His main research includes understanding molecular basis various forms of non-diabetic hypoglycemia in children and identifying novel therapies in hypoglycemia/hyperinsulinism. He has been a speaker at various international and national meetings and has been primary investigator for various investigational studies and clinical trials.

Dr. David Weinstein
Passage Bio, US

Following his graduation from Trinity College (CT) and Harvard Medical School, Dr. Weinstein did a residency, chief residency, and fellowship in pediatric endocrinology at Boston Children’s Hospital. He subsequently obtained a Masters in Clinical Investigation from Harvard and MIT, and became Director of the Glycogen Storage Disease Program at Boston Children’s. In 2005, Dr. Weinstein moved to the University of Florida where he directed the Glycogen Storage Disease Program and became a tenured professor. He and his team moved to the University of Connecticut and Connecticut Children’s Medical Center in 2017 to perform gene therapy for GSD. In August 2020, he left the academic world to serve as the medical lead for the GMI gangliosidosis gene therapy trial at Passage Bio.

Dr. Weinstein has published over 100 manuscripts and 28 textbook chapters in the field of disorders of carbohydrate metabolism. He was named as one of the inaugural Goldwater Scholars in 1989. He is a former Jan Albrecht Award winner from the American Association for the Study of Liver Diseases, and he was the George Tucher Award winner from the Gerontological Society of America. In 2013, Dr. Weinstein was honored with the Order of the Smile international humanitarian award, and he was knighted in Poland as part of this recognition. He has also been inducted in the Rare Disease Research Hall of Fame.
**SAY HELLO TO OUR LATEST ADVISORS**

We are beyond excited to give a warm welcome and applause to our latest Scientific Advisory Board members; two outstanding world-class experts in complex hypoglycemia:

Dr. Mary-Elizabeth Patti and Dr. Joseph Wolfsdorf are dedicated to enhance the understanding of idiopathic ketotic hypoglycemia.

---

**Dr. Mary-Elizabeth Patti**
Joslin Diabetes Center, Harvard Medical School, Boston, US

Dr. Mary-Elizabeth Patti is a physician-scientist, serving as a Principal Investigator at Joslin Diabetes Center, Director of the Hypoglycemia Clinic, Co-Director of the Molecular Phenotyping Core, and Associate Professor of Medicine at Harvard Medical School.

Dr. Patti’s NIH-funded lab focuses on identification of molecular/epigenetic mechanisms by which nutritional exposures during early life increase diabetes risk in subsequent generations.

Translational studies are focused on mechanisms contributing to diabetes resolution and hypoglycemia after bariatric surgery.

Dr. Patti received her MD from Jefferson Medical College magna cum laude, internal medicine residency at the University of Pittsburgh, and endocrinology fellowship at Harvard. She is board-certified in endocrinology and metabolism.

Dr. Patti has held numerous leadership roles in the diabetes scientific community, including service as organizer of a diabetes-focused Keystone Symposium and chair of the American Diabetes Association Scientific Sessions Planning Committee.

She was elected to the American Society of Clinical Investigation in 2009 and to Fellowship in both the American College of Physicians and Obesity Society in 2014.

---

**Dr. Joseph Wolfsdorf**
Boston’s Children’s Hospital, Harvard Medical School, Boston, US

Professor of Pediatrics at Harvard Medical School and the first incumbent of the Boston Children’s Hospital Chair in Endocrinology. He served as the Director of the Diabetes Program at Boston Children’s Hospital for 35 years until June 2018.

From 1986-1997 he was also Chief of Pediatrics at Joslin Diabetes Center and Medical Director of the Pediatric Diabetes Treatment Unit of the New England Deaconess Hospital. Was a member of the Joslin Diabetes Center DCCT research team from 1984-1993. Served as Clinical Chief of the Division of Endocrinology, Boston Children’s Hospital from 1994-1998 and from 2006-2016. Dr. Wolfsdorf continues to be active in the practice of pediatric endocrinology. He has a special interest in disorders of carbohydrate metabolism (hypoglycemia disorders in children, glycogen storage disease) and, especially, the care of children, adolescents and young adults with diabetes mellitus. Professor Wolfsdorf is an author of more than 250 publications and has edited and contributed to 5 monographs and textbooks. He serves on the editorial board of Diabetes Care and Pediatric Diabetes, is an Associate Editor for Hormone Research in Pediatrics, and is the pediatric endocrinology section editor for all topics related to diabetes mellitus and hypoglycemia in UpToDate.

Dr. Wolfsdorf is the immediate Past President of the International Society of Pediatric and Adolescent Diabetes (ISPAD) for the period 2015-2018 and currently chairs the ISPAD eLearning committee.
What is ketotic hypoglycemia?

“Ketotic hypoglycemia may be unexplained, or idiopathic (IKH). This is a challenge and should urge for more research”

For the patients

In a normal person, fuel for the brain and the general cell metabolism primarily comes from the burning of sugar deposits (glycogen). When the glycogen stores are depleted, the body will switch to burn fat deposits. The fat burn lead to two fuels for the brain, both glucose (sugar) and ketone bodies. However, ketones in the blood will lead to nausea and eventually vomiting. This will lead to a vicious circle, where you cannot eat or drink sugar-rich items, which again leads to further fat burn and production of ketone bodies.

In a KH-patient, the glycogen stores are somehow insufficient. This leads to decreased fasting tolerance with earlier onset of fat burn and hence ketone bodies. In most patients, the hypoglycemia is relatively mild, and the ketone bodies help to provide fuel to the brain, which prevents loss of consciousness and convulsions. However, in relatively few patients, the condition is more severe, but still without an identified cause despite intense investigations in hormones and cell metabolism. Such patients are said to have "idiopathic" KH, or IKH, which simply means KH without any known cause.

For the doctors

Ketotic hypoglycemia can be seen in children because of growth hormone deficiency, certain deficiency, metabolic diseases with intact fatty acid consumption, including glycogen storage diseases (glycogenosis; GSD) type 0, III, VI, and IX, or disturbances in transport or metabolism of ketone bodies. When these diagnoses are excluded, ketotic hypoglycemia can be categorized as unexplained or idiopathic (IKH), otherwise known as accelerated starvation.

The primary treatment is dietary prevention with long carbohydrates (e.g. uncooked cornstarch) and frequent meals. In some more severely affected patients, continuous feeding may be needed through a gastrostomy tube.

Emergency treatment constitutes of oral or i.v. glucose, eventually i.m. glucagon, to raise the plasma glucose, which will prevent further lipolysis. However, the ketones can take hours to be eliminated. In more severely affected patients, the ketone production can be significant before hypoglycemia occurs, why recognition of increased ketones above approximately 1.5 mmol/L is important, sometimes already when the glucose concentration goes below 3.9 mmol/L (70 mg/dL).

Source: Professor Henrik Christesen, Odense University Hospital, Chair of the Scientific Advisory Board in KHI, Denmark

Source: Professor Henrik Christesen, Odense University Hospital, DK
Our families are united through a variety of social media channels. Ketotic Hypoglycemia International are active on LinkedIn, Instagram, Twitter, and Facebook. The Facebook Support Group is where the families are most active, and where we are sharing experiences and support each other to navigate the everyday-IKH-rollercoaster ride.

Ketotic Hypoglycemia International (KHI) is a global reaching family organization, uniting more than 1500 families from all over the world affected by idiopathic ketotic hypoglycemia. KHI aims to globally unite leading hypoglycemia experts with patients, caregivers, and healthcare providers, and to establish a greater understanding of IKH in the hopes to facilitate improved treatment options and greater quality of life for individuals suffering from IKH. The organization aims to challenge current perceptions and attitudes to expand the recognition that IKH is more than a normal variation and establish an international platform for future research collaboration. We are committed to supporting and advocating for those in the IKH community through our international KHI Parents Support Group by utilizing the contributions of general medical guidance made by our scientific advisory board, supporting research on the general well-being of IKH-families, and furthering research into IKH etiology, diagnosis, and management.

Since last year’s conference, we have published 2 scientific papers, presented and won a poster prize at the Engaging Citizen Science Conference in Århus, Denmark. The publications can be found below, and the poster can be found on page 14-15.

**What is this organization about?**

Ketotic Hypoglycemia International (KHI) is a global reaching family organization, uniting more than 1500 families from all over the world affected by idiopathic ketotic hypoglycemia. KHI aims to globally unite leading hypoglycemia experts with patients, caregivers, and healthcare providers, and to establish a greater understanding of IKH in the hopes to facilitate improved treatment options and greater quality of life for individuals suffering from IKH. The organization aims to challenge current perceptions and attitudes to expand the recognition that IKH is more than a normal variation and establish an international platform for future research collaboration. We are committed to supporting and advocating for those in the IKH community through our international KHI Parents Support Group by utilizing the contributions of general medical guidance made by our scientific advisory board, supporting research on the general well-being of IKH-families, and furthering research into IKH etiology, diagnosis, and management.

Since last year’s conference, we have published 2 scientific papers, presented and won a poster prize at the Engaging Citizen Science Conference in Århus, Denmark. The publications can be found below, and the poster can be found on page 14-15.

**Article 1**

*Orphanet Journal of Rare Diseases*


"Towards enhanced understanding of idiopathic ketotic hypoglycemia: a literature review and introduction of the patient organization, Ketotic Hypoglycemia International"

Danielle Drachmann, Erica Hoffmann, Austin Carrigg, Beccie Davis-Yates, Valerie Weaver, Paul Thornton, David A. Weinstein, Jacob S. Petersen, Pratik Shah, Henrik Thybo Christensen

**Article 2**

*JIMD Reports*

Published: 28 July 2021  |  [https://doi.org/10.1002/jmd2.12241](https://doi.org/10.1002/jmd2.12241)

"Ketotic hypoglycemia in patients with Down syndrome"

Danielle Drachmann, Austin Carrigg, David A. Weinstein, Jacob Sten Petersen, Henrik Thybo Christensen

Our families are united through a variety of social media channels. Ketotic Hypoglycemia International are active on LinkedIn, Instagram, Twitter, and Facebook. The Facebook Support Group is where the families are most active, and where we are sharing experiences and support each other to navigate the everyday-IKH-rollercoaster ride.
Ketotic hypoglycemia in patients with Down syndrome

Danielle Drachmann1,2,3, Austin Carrig1, David A. Weinstein1,4, Jacob Sten Petersen1,4, Astrid Janssens2,3,6, Henrik Thybo Christensen1,7,8


Conclusion

We present a case of co-created and family-organization driven research in the family organization Ketotic Hypoglycemia International, from the establishment of the organization to the scientific publication. This is the first demonstration of a possible high prevalence of ketotic hypoglycemia (KH) in Down syndrome (DS). Even though this finding needs to be confirmed in other research settings, identification of KH in DS could have a dramatic impact, as simple treatments with carbohydrate, protein and frequent meals may prevent KH attacks and, analogous to other conditions with KH, improve growth, stamina and prevent overeating and obesity. GY2δ deletion may contribute to KH in DS, resembling glycogen storage disease type 0. Our research is an example of a family-run patient organization driven and co-produced research, where novel observations may arise, not firstly caught by the health care system. This story can inspire others to adopt this approach to health research within research and patient groups.

CO-PRODUCED RESEARCH

10 steps that shaped a scientific discovery

1. The Beginning
Danielle Drachmann and her two kids, Noah and Savannah, diagnosed with low blood glucose and high ketones, without any known genetic cause: idiopathic ketotic hypoglycemia (KH).

2. The Organization
Danielle established Ketotic Hypoglycemia International (KH), established a scientific advisory board (SAB) with leading medical experts from all over the world – expanded with many KH families united in KH rapidly.

3. The Discovery
Melanie is a girl with DS who got diagnosed with KH. Her mother entered the support group and contacted Danielle with suspicion about a correlation between DS and KH after seeing posts in the online support group on social media.

4. The Survey
No association between DS and KH was ever reported in the literature. SAB members supported Austin and Danielle to draft out a survey. SAB consulted on survey draft.

5. The Data
A survey was sent to DS organizations and families worldwide.

6. The Findings
The results indicated an association. Want to know about the findings? Scan QR code 2 below.

7. The Nice Study
A SAB member found a mice study, giving a medical explanation (2) for why patients with DS could have KH. Want to know more about the mice study? Scan QR code 1 below.

8. The Publication
Scientific paper written by Austin, Danielle and medical experts in the SAB is published alongside a video abstract (3).

9. The Dissemination
Worldwide press attention for our findings.

2647 downloads in the first 6 months (average annual downloads for JIMD Reports: 441).

2nd most downloaded article in JIMD Reports in 2021.

10. The KH Experience
Clinical trials are now under way, more co-produced projects are in progress where caregivers and relatives work as researchers alongside medical experts.